Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | ACR | P10323 | 2/20 | 0.50 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2775628 | 1.00 | CA1 (0.55) | CA1CA2CA12CA9CA14 | |
| SCHEMBL13617864 | 1.00 | CA1 (0.55) | CA1CA2CA12CA9CA14 | |
| Urea SCHEMBL20838278 | 0.83 | CA1 (0.70) | CA1CA2CA12CA9CA14 | |
| SCHEMBL30506553 | 0.82 | LOXL2 (0.54) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2773914 | 0.82 | LOXL2 (0.54) | CA1CA2CA12CA9CA14 | |
| SCHEMBL66472 | 0.82 | LOXL2 (0.54) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2773919 | 0.82 | LOXL2 (0.54) | CA1CA2CA12CA9CA14 | |
| SCHEMBL30008510 | 0.82 | LOXL2 (0.54) | CA1CA2CA12CA9CA14 | |
| SCHEMBL23600 | 0.80 | CA1 (0.80) | CA1CA2CA12CA9CA14 | |
| SCHEMBL28993944 | 0.80 | CA1 (0.80) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233842-B1 | BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARB) AGONISTS | KING S COLLEGE LONDON (GB) | 2025-03-26 | — | — | EP | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11584741-B2 | Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation | KING'S COLLEGE LONDON (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11401265-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | KING'S COLLEGE LONDON | 2022-08-02 | — | — | US | disclosed |
| US-20220204490-A1 | Substituted 4-[5-(Benzofuran-2-yl)-1,2,4-Oxadiazol-3-yl]Benzoic Acid Compounds for Use in Therapy for Neuropathic Pain | KING'S COLLEGE LONDON (GB) | 2022-06-30 | — | — | US | disclosed |
| US-20220169621-A1 | OXADIAZOLES FOR USE IN CONTROLLING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LTD. (IN) | 2022-06-02 | — | — | US | disclosed |
| EP-3976028-A1 | SUBSTITUTED 4-[5-(BENZOFURAN-2-YL)-1,2,4-OXADIAZOL-3-YL]BENZOIC ACID COMPOUNDS FOR USE IN THERAPY FOR NEUROPATHIC PAIN | King's College London (GB) | 2022-04-06 | — | — | EP | disclosed |
| US-11286242-B2 | Oxadiazoles for use in controlling phytopathogenic fungi | PI INDUSTRIES LTD. (IN) | 2022-03-29 | — | — | US | disclosed |
| CN-109415356-B | Crystalline forms of 4- (5- (4, 7-dimethylbenzofuran-2-yl) -1,2, 4-oxadiazol-3-yl) benzoic acid and methods for their preparation | 伦敦皇家学院 | 2022-03-08 | — | — | CN | disclosed |
| US-20210230151-A1 | Crystalline Forms of 4-(5-(4,7-Dimethylbenzofuran-2-YL)-1,2,4-Oxadiazol-3-YL)Benzoic Acid and Processes for Their Preparation | KING'S COLLEGE LONDON (GB) | 2021-07-29 | — | — | US | disclosed |
| US-20050033055-A1 | Edg receptor agonists | MERCK SHARP & DOHME CORP. | 2005-02-10 | — | — | US | disclosed |
| EP-1469863-A2 | SELECTIVE S1P1/EDG1 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-1470137-A1 | EDG RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-1406632-A2 | SUBSTITUTED 3-ARYL-5-ARYL- 1,2,4]-OXADIAZOLES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20040058894-A1 | Selective S1P1/Edg1 receptor agonists | DOHERTY GEORGE A (US) | 2004-03-25 | — | — | US | disclosed |
| WO-2003062252-A1 | EDG RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003061567-A2 | SELECTIVE S1P1/EDG1 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003062248-A2 | N-(BENZYL)AMINOALKYLCARBOXYLATES, PHOSPHINATES, PHOSPHONATES AND TETRAZOLES AS EDG RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2002100826-A2 | SUBSTITUTED 3-ARYL-5-ARYL-[1,2,4]-OXADIAZOLES AND ANALOGS | CYTOVIA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286242-B2 | Oxadiazoles for use in controlling phytopathogenic fungi | OXA1L, CYP51A1, CYP1A1 | CA1 3515/4885CA2 2964/4885CA12 3224/4885 |
| US-20040058894-A1 | Selective S1P1/Edg1 receptor agonists | S1PR1, S1PR3, S1PR2 | CA1 4551/4885CA2 4477/4885CA12 4545/4885 |
| US-11401265-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | RARB, RARA, RXRB | CA1 3686/4885CA2 3851/4885CA12 4441/4885 |
| US-11584741-B2 | Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation | RARB, RXRB, RARA | CA1 1838/4885CA2 2392/4885CA12 3766/4885 |
| US-20050033055-A1 | Edg receptor agonists | EDNRA, EDNRB, GPR65 | CA1 3362/4885CA2 3141/4885CA12 3455/4885 |
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, API5 | CA1 3257/4885CA2 3261/4885CA12 4725/4885 |
| US-20210230151-A1 | Crystalline Forms of 4-(5-(4,7-Dimethylbenzofuran-2-YL)-1,2,4-Oxadiazol-3-YL)Benzoic Acid and Processes for Their Preparation | RARB, RXRB, RARA | CA1 2715/4885CA2 2591/4885CA12 4241/4885 |
| US-20220204490-A1 | Substituted 4-[5-(Benzofuran-2-yl)-1,2,4-Oxadiazol-3-yl]Benzoic Acid Compounds for Use in Therapy for Neuropathic Pain | OPRK1, TRPV1, TRPA1 | CA1 2854/4885CA2 633/4885CA12 3544/4885 |
| US-20220169621-A1 | OXADIAZOLES FOR USE IN CONTROLLING PHYTOPATHOGENIC FUNGI | OXA1L, CYP51A1, CYP1A1 | CA1 3515/4885CA2 2964/4885CA12 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.